Anixa Biosciences (NASDAQ:ANIX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Anixa Biosciences (NASDAQ:ANIX) from a hold rating to a sell rating in a research report released on Saturday.

Several other research firms also recently weighed in on ANIX. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Friday, December 12th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Thursday, September 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.00.

Anixa Biosciences Stock Down 0.6%

NASDAQ ANIX opened at $3.18 on Friday. The firm has a market cap of $104.69 million, a PE ratio of -9.09 and a beta of 0.49. The company has a 50 day moving average price of $4.13 and a 200 day moving average price of $3.62. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $5.46.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new position in Anixa Biosciences in the second quarter worth approximately $33,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. acquired a new stake in shares of Anixa Biosciences during the 2nd quarter worth about $37,000. Marshall Wace LLP purchased a new stake in Anixa Biosciences in the 2nd quarter valued at about $39,000. Finally, World Investment Advisors acquired a new position in Anixa Biosciences in the third quarter valued at about $48,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.